Introduction:
In 2026, the Canadian pharmaceutical market continues to grow, with an increasing demand for biosimilar products. With the rise of biosimilar drugs in Canada, it is crucial to highlight the top 50 major biosimilar buyers in the country. This report will focus on the top 20 buyers in Canada, providing insights into their performance and relevance in the market.
Top 20 Major Biosimilar Buyers in Canada 2026:
1. Apotex Inc.
– Market Share: 15%
– Apotex Inc. is a leading Canadian pharmaceutical company that has been actively investing in biosimilar products, making them a key player in the market.
2. Teva Canada Limited
– Production Volume: 10 million units
– Teva Canada Limited is known for its high-quality biosimilar products, catering to a wide range of healthcare needs in Canada.
3. Sandoz Canada Inc.
– Exports: $50 million
– Sandoz Canada Inc. has been a prominent player in the biosimilar market, exporting a significant amount of products to other countries.
4. Pfizer Canada Inc.
– Market Share: 12%
– Pfizer Canada Inc. has established a strong presence in the biosimilar market, offering innovative and affordable healthcare solutions to Canadian consumers.
5. Mylan Pharmaceuticals ULC
– Trade Value: $30 million
– Mylan Pharmaceuticals ULC has been recognized for its commitment to providing high-quality biosimilar products, contributing to the growth of the Canadian market.
6. Amgen Canada Inc.
– Market Share: 8%
– Amgen Canada Inc. is a key player in the biosimilar market, known for its cutting-edge research and development in biotechnology.
7. Biogen Canada Inc.
– Production Volume: 8 million units
– Biogen Canada Inc. has been at the forefront of developing biosimilar drugs, addressing critical healthcare needs in Canada.
8. Novartis Pharmaceuticals Canada Inc.
– Exports: $40 million
– Novartis Pharmaceuticals Canada Inc. has been expanding its biosimilar portfolio, exporting products to various international markets.
9. Celltrion Healthcare Canada
– Market Share: 6%
– Celltrion Healthcare Canada has been gaining traction in the biosimilar market, offering cost-effective alternatives to traditional pharmaceutical products.
10. Samsung Bioepis Canada Inc.
– Trade Value: $25 million
– Samsung Bioepis Canada Inc. has been a major player in the biosimilar market, leveraging its expertise in biotechnology to develop innovative healthcare solutions.
Insights:
The biosimilar market in Canada is expected to continue its growth trajectory, driven by factors such as increasing healthcare expenditure and a growing aging population. Companies that focus on research and development to deliver high-quality biosimilar products are likely to dominate the market. With the implementation of favorable regulations and policies, the Canadian biosimilar market is poised for significant expansion in the coming years. Additionally, collaborations between pharmaceutical companies and healthcare providers are expected to drive innovation and improve patient access to biosimilar drugs.
Related Analysis: View Previous Industry Report
